CSL Biotherapies, and its parent company, CSL Limited have reached an agreement with Merck & Co., Inc. on rights to market and distribute Afluria® in the United States under an exclusive, six-year agreement effective September 3, 2009. Merck has the exclusive right to sell and distribute Afluria® in the United States beginning with the 2010-2011 influenza season. The manufacture, filling and packaging of Afluria® will continue and will not change with this agreement; CSL Ltd. will retain the Afluria® license.
For information on prebooking Afluria® for the 2010-2011 season, please visit www.merckvaccines.com/afluria
or call the Merck Vaccine Customer Center at
For any questions relating to Afluria® 2009-2010, please contact
Afluria® 2009-2010 Prescribing Information (Revised 11/2009)
CSL Biotherapies' plans or capacity for manufacturing and delivering its pandemic Influenza A (H1N1) Monovalent Vaccine to US Human Health Services (HHS) are not affected by the seasonal influenza vaccine agreement. For any questions relating to CSL Biotherapies' Influenza A (H1N1) 2009 Monovalent Vaccine, please contact
CSL Biotherapies' Influenza A (H1N1) 2009 Monovalent Vaccine Prescribing Information